Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Natera Inc (NQ: NTRA )

109.61 -0.40 (-0.36%)
Streaming Delayed Price Updated: 11:59 AM EDT, Jun 28, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Natera Inc

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why ResMed Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Missfresh Limited (NASDAQ: MF) jumped 168% to $1.38 after the company announced entry of share purchase agreements for financing and business acquisition. 
Via Benzinga
Why Natera Stock Is Soaring Today
This DNA testing leader passed the test in Q2. 
Via The Motley Fool
Earnings Scheduled For August 3, 2023
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million. 
Via Benzinga
Natera Earnings Preview
Via Benzinga
Investors Cheer Jobs Report: Why Are These 5 Stocks And 5 ETFs Shining On Friday?
Via Benzinga
Atlassian, Universal Display, Booking, Dropbox And Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones gaining around 150 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
What 7 Analyst Ratings Have To Say About Natera
Via Benzinga
Analyst Expectations for Natera's Future
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Natera Reports Second Quarter 2023 Financial Results
From Natera, Inc.
Via Business Wire
Natera to Participate in Canaccord Genuity 43rd Annual Growth Conference
From Natera, Inc.
Via Business Wire
Natera Files Patent Infringement Suit Against NeoGenomics
From Natera, Inc.
Via Business Wire
Natera Announces Completion of Enrollment to the Randomized, Phase III ALTAIR Trial of Signatera™ in Colorectal Cancer
From Natera, Inc.
Via Business Wire
Natera to Report its Second Quarter 2023 Results on August 3rd
From Natera, Inc.
Via Business Wire
Court Issues Favorable Ruling for Natera in False Advertising Trial Against CareDx; Eliminates all Damages
From Natera, Inc.
Via Business Wire
Natera to Participate in Goldman Sachs 44th Annual Global Healthcare Conference
From Natera, Inc.
Via Business Wire
Natera Announces Data from the ProActive Study that Supports Prospera™ Kidney as an Early Indicator of Transplant Rejection
From Natera, Inc.
Via Business Wire
New Natera Data to be Presented at the 2023 ASCO Annual Meeting in 13 Studies Across Multiple Cancer Types
From Natera, Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Jury Rules in Favor of Natera, Finding all Asserted Patents Valid and Infringed by ArcherDX/Invitae; Awards $19.35 Million in Past Damages for Royalties and Lost Profits
From Natera, Inc.
Via Business Wire
Natera Reports First Quarter 2023 Financial Results
From Natera, Inc.
Via Business Wire
Natera Announces New Publication from I-SPY2 Trial Reinforcing Clinical Utility of Signatera™ for Breast Cancer Patients in the Neoadjuvant Setting
From Natera, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For May 5, 2023
Via Benzinga
Natera Announces First Quarter 2023 Earnings Conference Call
From Natera, Inc.
Via Business Wire
Natera Announces New Signatera™ MRD Data at 2023 AACR Annual Meeting
From Natera, Inc.
Via Business Wire
New Publication Demonstrates Utility of Natera’s Signatera™ Test in Melanoma
From Natera, Inc.
Via Business Wire
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy. 
Via InvestorPlace
Catalent Stock Showing Improved Relative Strength Rating
On Friday, Catalent stock earned a positive adjustment to its Relative Strength (RS) Rating, from 63 to 74. 
Via Investor's Business Daily
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.